Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients.
Immune changes induced by the CCR5 antagonist maraviroc raise the question of an impairment of responses to vaccines. We evaluated the immunogenicity of the adjuvanted pandemic influenza A-H1N1v 2009 vaccine in HIV-1-infected patients with suppressed HIV viremia with or without a maraviroc-containing regimen. Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine.
Canestri
Ana
A
AP-HP, Hôpital Pitié-Salpêtrière, Service des Maladies Infectieuses et Tropicales, Paris, France. ana.canestri@psl.aphp.fr
Krivine
Anne
A
Assoumou
Lambert
L
Le Corre
Monique
M
Rozenberg
Flore
F
Marcelin
Anne-Geneviève
AG
Schneider
Luminita
L
Samri
Assia
A
Carcelain
Guislaine
G
Autran
Brigitte
B
Katlama
Christine
C
Guihot
Amélie
A
D000328:Adult; D000368:Aged; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003510:Cyclohexanes / Q000494:pharmacology*; D004196:Disease Outbreaks; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000276:immunology*; D007252:Influenza Vaccines / Q000494:pharmacology*; D007251:Influenza, Human; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D014230:Triazoles / Q000494:pharmacology*
D003510:Cyclohexanes; D007252:Influenza Vaccines; D014230:Triazoles; D000077592:Maraviroc